Merck’s 2013 sales fell by 7 per cent

Merck & Co has posted its full-year financial results for 2013, showing a 7 per cent drop in sales income compared with 2012.

The company has blamed patent expiries for the fall in worldwide earnings to 44 billion US dollars in 2013.

"In 2013 we took decisive action to sharpen our focus, reduce our cost structure and advance our innovative research and development.

"This year we are excited about the potential of our near- and long-term pipeline, poised for long-term growth and committed to providing continued value to patients, customers and our shareholders."

Kenneth Frazier, chief executive and chairman, Merck.

Related news:

Merck's earnings miss slightly but it was not the 'mega-miss' some anticipated (FiercePharma).

Merck & Co results disappoint, as the firm takes a hit from generics (The Pharma Letter).

Reference links:

Merck announces fourth-quarter and full-year 2013 financial results (Merck press release).